Jo Love

Suggest Changes
Learn More
BACKGROUND To assess the efficacy, safety, tolerability and pharmacokinetics of BIBF 1120 in patients with stage IIIB/IV non-small-cell lung cancer (NSCLC). METHODS Patients with locally advanced(More)
  • 1